Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

7.1K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.1K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.5K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting AATF reprograms the tumor microenvironment and suppresses hepatocellular carcinoma via MIR100HG-TGF-β signaling.

Molecular therapy. Oncology·2026
Same author

Dietary bioactive compounds and inflammaging: Pro-inflammatory triggers and geroprotective countermeasures.

Ageing research reviews·2026
Same author

Apolipoprotein A-I as a Molecular Target of the Immunomodulatory Peptide Jusvinza: Mechanistic Insights From Affinity and In Silico Studies.

Journal of peptide science : an official publication of the European Peptide Society·2026
Same author

PPAR-δ is a potential modulator of central carbon metabolism in human adipocytes.

Bioinformation·2026
Same author

Reduction of Weight Gain by Modulating Mitochondrial Energy Coupling Efficiency Using a Bromo-Coenzyme Q10 analog (6-Br-Q0C10).

bioRxiv : the preprint server for biology·2026
Same author

Recent advances in our understanding of the gut microbiome: an analysis from the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology.

Gut·2026

Related Experiment Video

Updated: Feb 19, 2026

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

3.3K

NETosis in ischemic stroke: Mechanisms, implications, and therapeutic prospects.

Naveen Kumar Krishnamoorthy1, Manjunath Kalyan1, Vichitra Chandrasekaran1

  • 1Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, India; Centre for Experimental Pharmacology & Toxicology, Central Animal Facility, JSS Academy of Higher Education & Research, Mysuru 570015, India.

Pharmacology & Therapeutics
|February 17, 2026
PubMed
Summary

Neutrophil extracellular traps (NETosis) drive stroke damage by promoting clots and inflammation. Inhibiting NETosis shows promise for neuroprotection and improved recovery in ischemic stroke models.

Keywords:
Ischemic strokeNETosisNETs inhibitorsNeutrophil extracellular trapsThromboinflammation

More Related Videos

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

1.6K
A Cell Culture Model for Studying the Role of Neuron-Glia Interactions in Ischemia
11:36

A Cell Culture Model for Studying the Role of Neuron-Glia Interactions in Ischemia

Published on: November 14, 2020

10.2K

Related Experiment Videos

Last Updated: Feb 19, 2026

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

3.3K
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

1.6K
A Cell Culture Model for Studying the Role of Neuron-Glia Interactions in Ischemia
11:36

A Cell Culture Model for Studying the Role of Neuron-Glia Interactions in Ischemia

Published on: November 14, 2020

10.2K

Area of Science:

  • Neuroscience
  • Immunology
  • Cardiovascular Research

Background:

  • Ischemic stroke causes significant neurological deficits due to secondary injury mechanisms.
  • Neutrophil extracellular traps (NETosis) are increasingly recognized as a key mediator linking innate immunity to thrombotic and inflammatory damage in stroke.

Purpose of the Study:

  • To review the central role of NETosis in ischemic stroke pathogenesis.
  • To highlight the potential of NET-targeted therapies for stroke treatment.

Main Methods:

  • Review of clinical and pre-clinical investigations on NETosis in ischemic stroke.
  • Analysis of experimental strategies targeting NET formation and dissolution.

Main Results:

  • NETosis contributes to thrombus formation, blood-brain barrier disruption, and neuroinflammation post-stroke.
  • NET-related markers correlate with stroke severity and poor outcomes.
  • NET inhibition strategies demonstrate neuroprotective effects in animal models.

Conclusions:

  • NETosis is a critical factor in stroke-induced thrombosis, BBB damage, and sustained inflammation.
  • Targeting NETosis presents a promising therapeutic avenue for ischemic stroke, though clinical translation faces challenges.